Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry - Leosdottir, Margret, MD, PhD; Schubert, Jessica, MD; Brandts, Julia, MD; Gustafsson, Stefan, PhD; Cars, Thomas, PhD; Sundström, Johan, MD, PhD; Jernberg, Tomas, MD, PhD; Ray, Kausik K., MBchB, MD, FMedSci; Hagström, Emil, MD, PhD (Journal of the American College of Cardiology, 2025)
Keywords: Aged; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - therapeutic use; Cardiology and Cardiovascular Disease; Cardiovascular; Cholesterol, LDL - blood; Clinical Medicine; combination therapy; Drug Therapy, Combination; ezetimibe; Ezetimibe - administration & dosage; Ezetimibe - therapeutic use; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Kardiologi och kardiovaskulära sjukdomar; Klinisk medicin; lipid-lowering therapy; low-density lipoprotein cholesterol; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - drug therapy; Registries; statin; Time Factors; Treatment Outcome; PCSK9i; LDL-C; low-density lipoprotein cholesterol; myocardial infarction; ACS; lipid-lowering therapy; acute coronary syndrome; statin; ezetimibe; LLT; MACE; combination therapy; major adverse cardiovascular events; MI; proprotein convertase subtilisin/kexin type 9 inhibitor